ReviewAntibiotics (Basel, Switzerland)2022
Overview of Bioactive Fungal Secondary Metabolites: Cytotoxic and Antimicrobial Compounds.
Review in Antibiotics (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed.
- Article
- Multi-omics characterization of Saccharomyces boulardii in the biocontrol of Aspergillus flavus.Archives of microbiology · 2026Article
- Water Soluble-Nitrogenous Secondary Metabolites From Talaromyces annesophieae MD2 Exhibit Anti-Bacterial, Anti-Cancer, Anti-Oxidant, and Cytoprotective Activities.MicrobiologyOpen · 2026Article
- Beyond Taxonomy: A Matrix-Trait-Function Framework for Predictive Selection of Non-Microorganisms · 2026Review
- Draft genome sequence of Talaromyces trachyspermus, a biocontrol fungus isolated from broomrape.G3 (Bethesda, Md.) · 2026Article
- 2A peptides enable simplified discovery and heterologous production of fungal bioactive metabolites in Yarrowia lipolytica.Applied microbiology and biotechnology · 2026Article
- Harnessing Endophytic Fungi as a Sustainable Source of Novel Anticancer Agents: Opportunities, Challenges, and Future Directions.Molecules (Basel, Switzerland) · 2026Review
- ZnCoACS omega · 2026Article
- Amazonian Fungal Diversity and the Potential of Basidiomycetes as Sources of Novel Antimicrobials.Biology · 2026Review
- All you need is fungi: Exploring secondary metabolites as a source of novel amoebicidal agents.Genetics and molecular biology · 2026Article
- Assessment of antibacterial and anti-biofilm activities of marine fungal epiphytes associated with red and green algae of the Kenyan coast.Biotechnology notes (Amsterdam, Netherlands) · 2026Article
- Bio-guided discovery of antibacterial metabolites fromJournal of enzyme inhibition and medicinal chemistry · 2025Article
- Secondary metabolites of Minutisphaera thailandensis and Hongkongmyces kokensis revealed by LC-QTOF-MS and their antimicrobial and cytotoxic activities.Scientific reports · 2025Article
- Marine Fungal Metabolites: A Promising Source for Antibiofilm Compounds.Molecules (Basel, Switzerland) · 2025Review
- Fungal metabolite Ochratoxin A inhibits MrkD1P of multidrug-resistant Klebsiella pneumoniae: Integrated computational and in vitro validation.Journal of computer-aided molecular design · 2025Article
- Genome sequencing and physiological characterization of three Neoarthrinium moseri strains.BMC microbiology · 2025Article
- Analyzing the Challenges and Opportunities Associated With Harnessing New Antibiotics From the Fungal Microbiome.MicrobiologyOpen · 2025Review
- Structural Features and In Vitro Antiviral Activities of Fungal Metabolites Sphaeropsidins A and B Against Bovine Coronavirus.International journal of molecular sciences · 2025Article
- In Vitro Antiviral Activity of the Fungal Metabolite 6-Pentyl-α-Pyrone Against Bovine Coronavirus: A Translational Study to SARS-CoV-2.Veterinary sciences · 2025Article
- Exploring the Bioactive Secondary Metabolites of Two ArgentineJournal of fungi (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Microorganisms are known as important sources of natural compounds that have been studied and applied for different purposes in distinct areas. Specifically, in the pharmaceutical area, fungi have been explored mainly as sources of antibiotics, antiviral, anti-inflammatory, enzyme inhibitors, hypercholesteremic, antineoplastic/antitumor, immunomodulators, and immunosuppressants agents. However, historically, the high demand for new antimicrobial and antitumor agents has not been sufficiently attended by the drug discovery process, highlighting the relevance of intensifying studies to reach sustainable employment of the huge world biodiversity, including the microorganisms. Therefore, this review describes the main approaches and tools applied in the search for bioactive secondary metabolites, as well as presents several examples of compounds produced by different fungi species with proven pharmacological effects and additional examples of fungal cytotoxic and antimicrobial molecules. The review does not cover all fungal secondary metabolites already described; however, it presents some reports that can be useful at any phase of the drug discovery process, mainly for pharmaceutical applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.